YORK, England – Intelsius, a DGP company, a designer, manufacturer, and distributor of temperature-controlled packaging solutions, introduced revisions to its PharmaTherm™ line of solutions to pharmaceutical industry professionals today at the 13th Annual Cool Chain Europe Summit in Luxembourg.
“Intelsius is refining one of our best-selling product lines to stay ahead of the constantly changing pharmaceutical industry,” said David Walsh, CEO, Intelsius. “All three new sizes provide optimal thermal protection for pharmaceutical products.” In addition, PharmaTherm R solutions are regulatory compliant to meet the qualifications in the new GDP Guidelines for the EU that expanded and became more uniformly regulated in September 2013.
PharmaTherm R solutions are pre-qualified to the Intelsius High-Performance profile and maintain payload integrity during shipments for 72 hours. In addition, the three sizes available today utilize the same size coolant across the range and have a universal pack-out making them easy to assemble, operationally friendly, tamper-evident, and economical to ship.
“These additions allow more flexibility in payload sizes, making them an Intelsius innovation,” said Steve Healy, Intelsius global director of sales. With interchangeable components and common features across the range, suitable solutions are available for all temperature-controlled shipping requirements. The PharmaTherm family now offers pre-qualified 72 hours 2-8 degrees C, 96 hours 15-25 degrees C, PCM, and dry ice solutions.
“The revised PharmaTherm line of products will help our customers save on storage space and shipping costs,” said Walsh. “As we continue to protect life’s most precious cargo, we create innovative products that provide intelligent solutions.” PharmaTherm products maintain appropriate temperatures and keep products safe while being transported. In addition, its discreet design keeps the contents confidential.
Intelsius serves many organizations, including government agencies, leading pharmaceutical, biopharmaceutical, and clinical research industries to major laboratories. In addition, Intelsius is the preferred response partner for human and veterinary epidemic and pandemic events in the UK and the Republic of Ireland.
Incorporated in 1998, Intelsius is a subsidiary of DGP Life Science Ltd, headquartered in York, United Kingdom. With a strong focus on developing environmentally sustainable products and procedures, the company offers solutions to ensure the integrity of customers’ products and samples. Intelsius has a growing global presence with manufacturing facilities, distribution hubs, and local offices worldwide, including North America, Europe, and Asia. For more information, visit www.intelsius.com.
Media Contact: Tammy Moran, Intelsius, +1 317.536.9950 or firstname.lastname@example.org